SESSION TITLE: ILD Case Report Posters I
SESSION TYPE: Case Report Poster
PRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Rheumatoid arthritis (RA) is commonly associated with serositis, including pleural effusions. This case demonstrates the benefit of using rituximab (RTX) in the treatment of this condition.
METHODS: A 50 year old female non smoker with long standing RA on immunosuppression was investigated for bilateral pleural effusions unresponsive to empiric TB treatment. She subsequently developed a pericardial effusion resulting in tamponade and required surgical intervention. Histology of pleural and pericardial biopsies on VATS was consistent with serositis.
RESULTS: She was treated with rituximab and improved dramatically.
CONCLUSIONS: Rituximab (RTX) is a chimeric monoclonal antibody with activity against CD20 expressed by B cells. Keir et al showed an improvement in outcomes with use of RTX as rescue therapy in patients with advanced pulmonary disease related to CTD . This is the first recorded case of life-threatening rheumatoid-related serositis responsive to RTX.
CLINICAL IMPLICATIONS: In cases of RA-related pleural or pericardial effusions and ILD, consideration should be given to treatment with RTX.
DISCLOSURE: The following authors have nothing to disclose: Deirdre Fitzgerald, Michael Henry
No Product/Research Disclosure Information